Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
暂无分享,去创建一个
W. Poewe | O. Rascol | G. Stebbins | Nir Giladi | C. Goetz | C. Sampaio | R. Holloway | C. Moore | M. Yahr | C. Counsell | G. Wenning | Lisa Seidl | C. Moore
[1] G. Canter,et al. A METHOD FOR EVALUATING DISABILITY IN PATIENTS WITH PARKINSON'S DISEASE , 1961, The Journal of nervous and mental disease.
[2] B. Djahanguiri,et al. The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.
[3] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[4] Webster Dd,et al. Critical analysis of the disability in Parkinson's disease. , 1968 .
[5] D. Webster. Critical analysis of the disability in Parkinson's disease. , 1968, Modern treatment.
[6] R. Marttila,et al. DISABILITY AND PROGRESSION IN PARKINSON'S DISEASE , 1977, Acta Neurologica Scandinavica.
[7] M. M. Maier Hoehn. Parkinsonism treated with levodopa: progression and mortality. , 1983, Journal of neural transmission. Supplementum.
[8] Parkinsonism treated with levodopa: progression and mortality. , 1983 .
[9] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[10] S. Fahn. Unified Parkinson's Disease Rating Scale , 1987 .
[11] No evidence for an association between glyoxalase I and haptoglobin in nine Spanish populations. , 1987, Human heredity.
[12] Kathryn M. Culig,et al. MRI Findings in Normal Aging and Alzheimer's Disease , 1987 .
[13] C. Tanner,et al. Progression of Parkinson's disease without levodopa , 1987, Neurology.
[14] N. Reynolds,et al. Factor analysis of Parkinson's impairment. An evaluation of the final common pathway. , 1987, Archives of neurology.
[15] L. Amaducci,et al. Evaluation of Parkinson's disease: reliability of three rating scales. , 1988, Neuroepidemiology.
[16] J. Jankovic,et al. Variable expression of Parkinson's disease , 1990, Neurology.
[17] B. Everitt,et al. Scales for rating motor impairment in Parkinson's disease: studies of reliability and convergent validity. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[18] Giuliano Geminiani,et al. Interobserver reliability between neurologists in training of Parkinson's disease rating scales. A multicenter study , 1991, Movement disorders : official journal of the Movement Disorder Society.
[19] L. Amaducci,et al. Evaluation of Parkinson's disease: a new approach to disability. , 1991, Neuroepidemiology.
[20] M. Pinter,et al. Quantification of motor deficit in Parkinson's disease with a motor performance test series , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[21] J. Morris,et al. Reliability of the columbia scale for assessing signs of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[22] M Schulzer,et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.
[23] A. H. Zwinderman,et al. Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale , 1994, Movement disorders : official journal of the Movement Disorder Society.
[24] P. Martínez-Martín,et al. Unified Parkinson's disease rating scale characteristics and structure , 1994, Movement disorders : official journal of the Movement Disorder Society.
[25] T. Ishikawa,et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] J. Hubble,et al. Pramipexole in patients with early Parkinson's disease. , 1995, Clinical neuropharmacology.
[27] E. van der Velde,et al. Clinical course of patients with idiopathic Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[28] J. Friedman,et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease , 1997, Neurology.
[29] A. Lieberman,et al. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study , 1997, Neurology.
[30] R. Fitzpatrick,et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. , 1997, Age and ageing.
[31] M. Guttman. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease , 1997, Neurology.
[32] Z. Faulkes,et al. A map of distal leg motor neurons in the thoracic ganglia of four decapod crustacean species. , 1997, Brain, behavior and evolution.
[33] C. Marsden,et al. Abstracts. Third international dystonia symposium , 1997 .
[34] D. Brooks,et al. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. , 1997, Clinical neuropharmacology.
[35] G. Stebbins,et al. Factor structure of the unified Parkinson's disease rating scale: Motor examination section , 1998, Movement disorders : official journal of the Movement Disorder Society.
[36] M. Hely,et al. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years , 1999, Journal of neurology, neurosurgery, and psychiatry.
[37] M. Pinter,et al. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study , 1999, Journal of neurology, neurosurgery, and psychiatry.
[38] D. Price,et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm , 1999, PAIN.
[39] A. Lang,et al. Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off‐state , 1999, Movement disorders : official journal of the Movement Disorder Society.
[40] I Litvan,et al. Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study , 2000, Neurology.
[41] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.
[42] G. Stebbins,et al. Differential progression of motor impairment in levodopa‐treated Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[43] Susan L. Mitchell,et al. Patterns of Outcome Measurement in Parkinson’s Disease Clinical Trials , 2000, Neuroepidemiology.
[44] A Schrag,et al. The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.
[45] A. Bonnet. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[46] J. Unterrainer,et al. Measuring the progression of idiopathic Parkinson's disease with [123I] β-CIT SPECT , 2000, Journal of Neural Transmission.
[47] R M Werner,et al. The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.
[48] S B Bird,et al. Clinically significant changes in pain along the visual analog scale. , 2001, Annals of emergency medicine.
[49] A. Stiggelbout,et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[50] R. Hills,et al. Evaluating drug treatments for Parkinson's disease: how good are the trials? , 2002, BMJ : British Medical Journal.
[51] Andrew J. Lees,et al. Management of Parkinson's disease: An evidence‐based review , 2002, Movement disorders : official journal of the Movement Disorder Society.
[52] Michael P McDermott,et al. Development and testing of the Parkinson's disease quality of life scale , 2003, Movement Disorders.
[53] W. Poewe,et al. The natural history of parkinson's disease , 1998, Journal of neurology.